Our high-purity Tirzepatide is a dual GLP-1 and GIP receptor agonist developed for research applications in metabolic disorders. This compound shares structural similarities with semaglutide pen formulations but offers unique dual agonist properties.
The white lyophilized powder maintains 99% purity and is supplied in research-grade vials. As a novel peptide therapeutic candidate, Tirzepatide demonstrates promising effects on glucose regulation and weight management in preclinical studies.
Research indicates potential applications in:
Our semaglutide pen alternative offers researchers a tool for comparative studies of incretin-based therapies. The compound's extended half-life and dual mechanism make it particularly valuable for chronic metabolic condition research.
Note: This product is for research use only. Not for human consumption. Proper handling procedures should be followed by qualified researchers.